RNA-Sequencing, Connectivity Mapping, and Molecular Docking to Investigate Ligand-Protein Binding for Potential Drug Candidates for the Treatment of Wilms Tumor

Abstract

The funding was mainly used for data analysis and interpretation, and the costs incurred during the manuscript preparation Background:Wilms tumor, or nephroblastoma, is a malignant pediatric embryonal renal tumor that has a poor prognosis. This study aimed to use bioinformatics data, RNA-sequencing, connectivity mapping, molecular docking, and ligand-protein binding to identify potential targets for drug therapy in Wilms tumor. Material/Methods:Wilms tumor and non-tumor samples were obtained from high throughput gene expression databases, and differentially expressed genes (DEGs) were analyzed using the voom method in the limma package. The overlapping DEGs were obtained from the intersecting drug target genes using the Connectivity Map (CMap) database, and systemsDock was used for molecular docking. Gene databases were searched for gene expression profiles for complementary analysis, analysis of clinical significance, and prognosis analysis to refine the study. Results:From 177 cases of Wilms tumor, there were 648 upregulated genes and 342 down-regulated genes. Gene Ontology (GO) enrichment analysis showed that the identified DEGs that affected the cell cycle. After obtaining 21 candidate drugs, there were seven overlapping genes with 75 drug target genes and DEGs. Molecular docking results showed that relatively high scores were obtained when retinoic acid and the cyclin-dependent kinase inhibitor, alsterpaullone, were docked to the overlapping genes. There were significant standardized mean differences for three overlapping genes, CDK2, MAP4K4, and CRABP2. However, four upregulated overlapping genes, CDK2, MAP4K4, CRABP2, and SIRT1 had no prognostic significance. Conclusions:RNA-sequencing, connectivity mapping, and molecular docking to investigate ligand-protein binding identified retinoic acid and alsterpaullone as potential drug candidates for the treatment of Wilms tumor.

<p>Knockdown of lncRNA ABHD11-AS1 Suppresses the Tumorigenesis of Pancreatic Cancer via Sponging miR-1231</p>

“…CDK2 has been confirmed to be cell cycle regulators in many cancers. 33,34 The present study was consistent with these backgrounds, revealing that ABHD11-AS1 knockdown notably induced G1 arrest in pancreatic cancer cells through inactivating CDK2 and cyclin E1. Meanwhile, our finding indicated that ABHD11-AS1 regulated the tumorigenesis of pancreatic cancer via sponging miR-1231, which led to the dysfunction of miR-1231 according to competitive endogenous RNA network.…”

“…7,8 Recent studies have shown a close correlation between lncRNAs and cancer progression. 9,10 For example, knockdown of LINC00324 could suppress the progression of liver cancer through upregulation of PU box binding protein. 11 Additionally, some lncRNAs have been confirmed to play key roles in the progression of pancreatic cancer.…”

The importance of precision medicine in modern molecular oncology

“…Typically, most cancers are caused by genetic mutation, so personal genomic and transcriptomic data analyses have been used to detect mutations in patients 1,2 . Furthermore, varies RNA‐seqs are used to predict the responses of drug treatment 3 …”

“…1,2 Furthermore, varies RNA-seqs are used to predict the responses of drug treatment. 3 Detection of cancer at early stages can significantly impact survival of cancer patients. Recently, many studies have shown that the cancer survival rates are continually increasing, indicating that the early cancer diagnosis and treatment have been improved.…”